Status:
COMPLETED
Bioavailability of Ubiquinol in Huntington Disease
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
Kaneka Corporation
Conditions:
Huntington Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nu...
Eligibility Criteria
Inclusion
- Have manifest Huntington disease
- Be 18 years of age or older
- Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
- Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit
Exclusion
- Have a history of intolerability of sensitivity to CoQ
- Have an unstable medical or psychiatric illness
- Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00980694
Start Date
September 1 2009
End Date
July 1 2012
Last Update
May 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester
Rochester, New York, United States, 14618